AI and the Pharmaceutical Industry — 2026-09-19 (Sat)

Overview

Pharma-AI investment coverage on September 19, 2026 was dominated by capital concentrating in drug discovery. Two stories anchored the day: China-based AI drug discovery startup Anew Labs raising $290 million at a $1.5 billion valuation, and Novo Nordisk partnering with Anthropic to build "Claude Science" into its efforts to shorten drug development timelines. The former highlights the scale of fundraising; the latter reflects a pairing between a major pharmaceutical company and a generative AI firm — two distinct dynamics converging on the same day.

By Category

Drug Discovery: Anew Labs' large raise confirms that capital continues to flow actively into AI drug discovery startups. The Novo Nordisk–Anthropic partnership shows an established pharmaceutical major embedding generative AI into its R&D process by teaming with an external LLM company, rather than building the capability in-house — a choice worth noting.

Enterprise AI Infrastructure & Governance: Reports linking Anew Labs to ByteDance point to a pattern of large tech companies entering AI drug discovery through spinouts. NAVER D2SF's investment in ImpriMed signals corporate venture capital interest in applying AI to precision medicine. Multiple articles also noted Anthropic expanding its activity in life sciences, pointing to a broadening of the company's business scope.

Reading the Investment Map

The only deal with a disclosed amount is Anew Labs' $290 million raise at a $1.5 billion valuation. Capital flow is consistently directed toward AI drug discovery startups, while the major pharmaceutical company in today's coverage (Novo Nordisk) is pursuing AI adoption through a partnership with an AI company (Anthropic) rather than a startup investment. The amount of NAVER D2SF's investment in ImpriMed was not disclosed, so its scale remains unclear.

What to Watch

Whether other investors follow into Anew Labs' funding round. 2. Whether concrete progress updates emerge on the Novo Nordisk–Anthropic partnership.